Sign in

    Dana Gravesh • Leerink Partners

    Daina Graybosch is a Senior Equity Research Analyst at Leerink Partners specializing in biotechnology and therapeutics, regularly covering major companies such as Merck (MRK) and numerous other biotech firms. Graybosch has issued over 34 stock recommendations with a reported success rate of 31% and an average transaction return of -16.3%, reflecting a challenging but active track record in equity research. She joined Leerink Partners in recent years after experience in both buy-side and sell-side analysis, furthering her specialization in healthcare equities. Graybosch holds professional securities licenses and is FINRA registered, underscoring her credentials in investment research.

    Dana Gravesh's questions to Compugen Ltd (CGEN) leadership

    Dana Gravesh's questions to Compugen Ltd (CGEN) leadership • Q2 2025

    Question

    An analyst from Leerink Partners, speaking for Dana Gravesh, asked for Compugen's view on Merck's recent Phase III success in ovarian cancer and how it affects their strategy, and also inquired about the early-stage pipeline's progress.

    Answer

    Chief Medical Officer Dr. Michelle Mahler clarified that Merck's trial was in a different patient population (platinum-resistant) and thus does not alter Compugen's strategy for its platinum-sensitive trial, though it validates the potential for checkpoint inhibitors. Chief Scientific Officer Dr. Eran Ophir added that the early-stage pipeline is advancing but details are being withheld for competitive reasons.

    Ask Fintool Equity Research AI